Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence (NASDAQ:XGN)

Management View - Exagen Inc. aims to address diagnostic delays in autoimmune diseases, with CEO John Aballi stating the company's commitment to owning the entire space and providing comprehensive care [2] - The company has set a revenue target of $70 million to $73 million for 2026, indicating a strategic focus on growth and expansion [2] - Exagen plans to expand its sales force and innovation cadence to support its growth objectives [2]